Comparison of Paclitaxel -Eluting Stents (Taxus) and Everolimus -Eluting Stents (Xience) in Left Main Coronary Artery Disease With 3 Years Follow-Up (from the ESTROFA-LM Registry)
Evidence regarding therapy with drug-eluting stents in the left main coronary artery (LM) is based mostly on trials performed with first-generation drug-eluting stents. The aim of this study was to evaluate long-term clinical outcomes after treatment for unprotected LM disease with paclitaxel-elutin...
Gespeichert in:
| Veröffentlicht in: | The American journal of cardiology 2013-03, Vol.111 (5), p.676-683 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 683 |
|---|---|
| container_issue | 5 |
| container_start_page | 676 |
| container_title | The American journal of cardiology |
| container_volume | 111 |
| creator | De la Torre Hernandez, Jose M., MD, PhD Alfonso, Fernando, MD, PhD Sanchez Recalde, Angel, MD Jimenez Navarro, Manuel F., MD, PhD Perez de Prado, Armando, MD Hernandez, Felipe, MD Abdul-Jawad Altisent, Omar, MD Roura, Gerard, MD Garcia Camarero, Tamara, MD Elizaga, Jaime, MD, PhD Rivero, Fernando, MD Gimeno, Federico, MD, PhD Calviño, Ramon, MD Moreu, Jose, MD Bosa, Francisco, MD, PhD Rumoroso, Jose R., MD, PhD Bullones, Juan A., MD Gallardo, Arsenio, MD Fernandez Diaz, Jose A., MD Ruiz Arroyo, Jose R., MD Aragon, Victor, MD Masotti, Monica, MD |
| description | Evidence regarding therapy with drug-eluting stents in the left main coronary artery (LM) is based mostly on trials performed with first-generation drug-eluting stents. The aim of this study was to evaluate long-term clinical outcomes after treatment for unprotected LM disease with paclitaxel-eluting stents (PES) and everolimus-eluting stents (EES). The ESTROFA-LM is a multicenter retrospective registry including consecutive patients with unprotected LM disease treated with PES or EES. A total of 770 patients have been included at 21 centers, 415 with treated PES and 355 with EES. Treatment with 2 stents was more frequent with PES (17% vs 10.4%, p = 0.007), whereas intravascular ultrasound was more frequently used with EES (35.2% vs 26%, p = 0.006). The 3-year death and infarction survival rates were 86.1% for PES and 87.3% for EES (p = 0.50) and for death, infarction, and target lesion revascularization were 83.6% versus 82% (p = 0.60), respectively. Definite or probable thrombosis was 1.6% for PES and 1.4% for EES (p = 0.80). The use of 2 stents, age, diabetes, and acute coronary syndromes were independent predictors of mortality. In the subgroup of distal lesions, the use of intravascular ultrasound was an independent predictor of better outcome. Comparison of propensity score–matched groups did not yield differences between the 2 stents. In conclusion, the results of this multicenter registry show comparable safety and efficacy at 3 years for PES and EES in the treatment of LM disease. The use of bifurcation stenting techniques in distal lesions was a relevant independent predictor for events. The use of intravascular ultrasound appears to have a positive impact on patients treated for LM distal disease. |
| doi_str_mv | 10.1016/j.amjcard.2012.11.019 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1288994706</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0002914912024526</els_id><sourcerecordid>1288994706</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-aeafddcbb2bd16eb6e4db5fcb8d09511f0082ace355409eb71c4158d2ac5aa9e3</originalsourceid><addsrcrecordid>eNqFks1uEzEQgFcIREPhEUCWuCSHDR7vT3YvoCgkBSlVUZMKOFlee7Z12F0H29s2z8UL4pAAUjlwGtv6ZmzPN1H0EugYKORvNmPRbqSwaswosDHAmEL5KBpAMSljKCF5HA0opSwuIS1PomfObcIWIMufRicsYZNkAtkg-jEz7VZY7UxHTE0-CdloL-6xIfG86b3ursnKY-cdGa7Ffe9GRHSKzG_Rmka3vfsX-6KxkzgiuiNLrD05F2E1M9Z0wu7I1HoM4b12KBySz9rfkIR8RWEdWZimMXfx1ZYMa2ta4m-QzFfry4vFNF6ek0u81s7b3eh59KQWjcMXx3gaXS3m69mHeHlx9nE2XcYyTQsfCxS1UrKqWKUgxyrHVFVZLatC0TIDqCktmJCYZFlKS6wmIFPIChXOMiFKTE6j4aHu1prvPTrPW-0kNo3o0PSOAyuKskwnNA_o6wfoxvS2C6_jkAYLkCS0DFR2oKQ1zlms-dbqNrSFA-V7q3zDj1b53ioH4MFqyHt1rN5XLao_Wb81BuDdAcDQjluNljv5S4PSFqXnyuj_XvH2QYUwCJ2WovmGO3R_f8Md45Sv9qO1nyxglKUZy5OficrK9g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1400213309</pqid></control><display><type>article</type><title>Comparison of Paclitaxel -Eluting Stents (Taxus) and Everolimus -Eluting Stents (Xience) in Left Main Coronary Artery Disease With 3 Years Follow-Up (from the ESTROFA-LM Registry)</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>De la Torre Hernandez, Jose M., MD, PhD ; Alfonso, Fernando, MD, PhD ; Sanchez Recalde, Angel, MD ; Jimenez Navarro, Manuel F., MD, PhD ; Perez de Prado, Armando, MD ; Hernandez, Felipe, MD ; Abdul-Jawad Altisent, Omar, MD ; Roura, Gerard, MD ; Garcia Camarero, Tamara, MD ; Elizaga, Jaime, MD, PhD ; Rivero, Fernando, MD ; Gimeno, Federico, MD, PhD ; Calviño, Ramon, MD ; Moreu, Jose, MD ; Bosa, Francisco, MD, PhD ; Rumoroso, Jose R., MD, PhD ; Bullones, Juan A., MD ; Gallardo, Arsenio, MD ; Fernandez Diaz, Jose A., MD ; Ruiz Arroyo, Jose R., MD ; Aragon, Victor, MD ; Masotti, Monica, MD</creator><creatorcontrib>De la Torre Hernandez, Jose M., MD, PhD ; Alfonso, Fernando, MD, PhD ; Sanchez Recalde, Angel, MD ; Jimenez Navarro, Manuel F., MD, PhD ; Perez de Prado, Armando, MD ; Hernandez, Felipe, MD ; Abdul-Jawad Altisent, Omar, MD ; Roura, Gerard, MD ; Garcia Camarero, Tamara, MD ; Elizaga, Jaime, MD, PhD ; Rivero, Fernando, MD ; Gimeno, Federico, MD, PhD ; Calviño, Ramon, MD ; Moreu, Jose, MD ; Bosa, Francisco, MD, PhD ; Rumoroso, Jose R., MD, PhD ; Bullones, Juan A., MD ; Gallardo, Arsenio, MD ; Fernandez Diaz, Jose A., MD ; Ruiz Arroyo, Jose R., MD ; Aragon, Victor, MD ; Masotti, Monica, MD ; ESTROFA-LM Study Group</creatorcontrib><description>Evidence regarding therapy with drug-eluting stents in the left main coronary artery (LM) is based mostly on trials performed with first-generation drug-eluting stents. The aim of this study was to evaluate long-term clinical outcomes after treatment for unprotected LM disease with paclitaxel-eluting stents (PES) and everolimus-eluting stents (EES). The ESTROFA-LM is a multicenter retrospective registry including consecutive patients with unprotected LM disease treated with PES or EES. A total of 770 patients have been included at 21 centers, 415 with treated PES and 355 with EES. Treatment with 2 stents was more frequent with PES (17% vs 10.4%, p = 0.007), whereas intravascular ultrasound was more frequently used with EES (35.2% vs 26%, p = 0.006). The 3-year death and infarction survival rates were 86.1% for PES and 87.3% for EES (p = 0.50) and for death, infarction, and target lesion revascularization were 83.6% versus 82% (p = 0.60), respectively. Definite or probable thrombosis was 1.6% for PES and 1.4% for EES (p = 0.80). The use of 2 stents, age, diabetes, and acute coronary syndromes were independent predictors of mortality. In the subgroup of distal lesions, the use of intravascular ultrasound was an independent predictor of better outcome. Comparison of propensity score–matched groups did not yield differences between the 2 stents. In conclusion, the results of this multicenter registry show comparable safety and efficacy at 3 years for PES and EES in the treatment of LM disease. The use of bifurcation stenting techniques in distal lesions was a relevant independent predictor for events. The use of intravascular ultrasound appears to have a positive impact on patients treated for LM distal disease.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/j.amjcard.2012.11.019</identifier><identifier>PMID: 23273715</identifier><identifier>CODEN: AJCDAG</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Antineoplastic Agents, Phytogenic - pharmacokinetics ; Cardiology ; Cardiovascular ; Cardiovascular disease ; Coronary Angiography ; Coronary Artery Disease - diagnostic imaging ; Coronary Artery Disease - surgery ; Coronary Restenosis - diagnostic imaging ; Coronary Restenosis - epidemiology ; Coronary Restenosis - prevention & control ; Coronary vessels ; Drug-Eluting Stents ; Everolimus ; Female ; Follow-Up Studies ; Heart attacks ; Humans ; Immunosuppressive Agents - pharmacology ; Incidence ; Male ; Paclitaxel - pharmacology ; Registries ; Retrospective Studies ; Sirolimus - analogs & derivatives ; Sirolimus - pharmacology ; Spain - epidemiology ; Stents ; Time Factors ; Treatment Outcome</subject><ispartof>The American journal of cardiology, 2013-03, Vol.111 (5), p.676-683</ispartof><rights>Elsevier Inc.</rights><rights>2013 Elsevier Inc.</rights><rights>Copyright © 2013 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Mar 1, 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-aeafddcbb2bd16eb6e4db5fcb8d09511f0082ace355409eb71c4158d2ac5aa9e3</citedby><cites>FETCH-LOGICAL-c448t-aeafddcbb2bd16eb6e4db5fcb8d09511f0082ace355409eb71c4158d2ac5aa9e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0002914912024526$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23273715$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>De la Torre Hernandez, Jose M., MD, PhD</creatorcontrib><creatorcontrib>Alfonso, Fernando, MD, PhD</creatorcontrib><creatorcontrib>Sanchez Recalde, Angel, MD</creatorcontrib><creatorcontrib>Jimenez Navarro, Manuel F., MD, PhD</creatorcontrib><creatorcontrib>Perez de Prado, Armando, MD</creatorcontrib><creatorcontrib>Hernandez, Felipe, MD</creatorcontrib><creatorcontrib>Abdul-Jawad Altisent, Omar, MD</creatorcontrib><creatorcontrib>Roura, Gerard, MD</creatorcontrib><creatorcontrib>Garcia Camarero, Tamara, MD</creatorcontrib><creatorcontrib>Elizaga, Jaime, MD, PhD</creatorcontrib><creatorcontrib>Rivero, Fernando, MD</creatorcontrib><creatorcontrib>Gimeno, Federico, MD, PhD</creatorcontrib><creatorcontrib>Calviño, Ramon, MD</creatorcontrib><creatorcontrib>Moreu, Jose, MD</creatorcontrib><creatorcontrib>Bosa, Francisco, MD, PhD</creatorcontrib><creatorcontrib>Rumoroso, Jose R., MD, PhD</creatorcontrib><creatorcontrib>Bullones, Juan A., MD</creatorcontrib><creatorcontrib>Gallardo, Arsenio, MD</creatorcontrib><creatorcontrib>Fernandez Diaz, Jose A., MD</creatorcontrib><creatorcontrib>Ruiz Arroyo, Jose R., MD</creatorcontrib><creatorcontrib>Aragon, Victor, MD</creatorcontrib><creatorcontrib>Masotti, Monica, MD</creatorcontrib><creatorcontrib>ESTROFA-LM Study Group</creatorcontrib><title>Comparison of Paclitaxel -Eluting Stents (Taxus) and Everolimus -Eluting Stents (Xience) in Left Main Coronary Artery Disease With 3 Years Follow-Up (from the ESTROFA-LM Registry)</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>Evidence regarding therapy with drug-eluting stents in the left main coronary artery (LM) is based mostly on trials performed with first-generation drug-eluting stents. The aim of this study was to evaluate long-term clinical outcomes after treatment for unprotected LM disease with paclitaxel-eluting stents (PES) and everolimus-eluting stents (EES). The ESTROFA-LM is a multicenter retrospective registry including consecutive patients with unprotected LM disease treated with PES or EES. A total of 770 patients have been included at 21 centers, 415 with treated PES and 355 with EES. Treatment with 2 stents was more frequent with PES (17% vs 10.4%, p = 0.007), whereas intravascular ultrasound was more frequently used with EES (35.2% vs 26%, p = 0.006). The 3-year death and infarction survival rates were 86.1% for PES and 87.3% for EES (p = 0.50) and for death, infarction, and target lesion revascularization were 83.6% versus 82% (p = 0.60), respectively. Definite or probable thrombosis was 1.6% for PES and 1.4% for EES (p = 0.80). The use of 2 stents, age, diabetes, and acute coronary syndromes were independent predictors of mortality. In the subgroup of distal lesions, the use of intravascular ultrasound was an independent predictor of better outcome. Comparison of propensity score–matched groups did not yield differences between the 2 stents. In conclusion, the results of this multicenter registry show comparable safety and efficacy at 3 years for PES and EES in the treatment of LM disease. The use of bifurcation stenting techniques in distal lesions was a relevant independent predictor for events. The use of intravascular ultrasound appears to have a positive impact on patients treated for LM distal disease.</description><subject>Aged</subject><subject>Antineoplastic Agents, Phytogenic - pharmacokinetics</subject><subject>Cardiology</subject><subject>Cardiovascular</subject><subject>Cardiovascular disease</subject><subject>Coronary Angiography</subject><subject>Coronary Artery Disease - diagnostic imaging</subject><subject>Coronary Artery Disease - surgery</subject><subject>Coronary Restenosis - diagnostic imaging</subject><subject>Coronary Restenosis - epidemiology</subject><subject>Coronary Restenosis - prevention & control</subject><subject>Coronary vessels</subject><subject>Drug-Eluting Stents</subject><subject>Everolimus</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Heart attacks</subject><subject>Humans</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Incidence</subject><subject>Male</subject><subject>Paclitaxel - pharmacology</subject><subject>Registries</subject><subject>Retrospective Studies</subject><subject>Sirolimus - analogs & derivatives</subject><subject>Sirolimus - pharmacology</subject><subject>Spain - epidemiology</subject><subject>Stents</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFks1uEzEQgFcIREPhEUCWuCSHDR7vT3YvoCgkBSlVUZMKOFlee7Z12F0H29s2z8UL4pAAUjlwGtv6ZmzPN1H0EugYKORvNmPRbqSwaswosDHAmEL5KBpAMSljKCF5HA0opSwuIS1PomfObcIWIMufRicsYZNkAtkg-jEz7VZY7UxHTE0-CdloL-6xIfG86b3ursnKY-cdGa7Ffe9GRHSKzG_Rmka3vfsX-6KxkzgiuiNLrD05F2E1M9Z0wu7I1HoM4b12KBySz9rfkIR8RWEdWZimMXfx1ZYMa2ta4m-QzFfry4vFNF6ek0u81s7b3eh59KQWjcMXx3gaXS3m69mHeHlx9nE2XcYyTQsfCxS1UrKqWKUgxyrHVFVZLatC0TIDqCktmJCYZFlKS6wmIFPIChXOMiFKTE6j4aHu1prvPTrPW-0kNo3o0PSOAyuKskwnNA_o6wfoxvS2C6_jkAYLkCS0DFR2oKQ1zlms-dbqNrSFA-V7q3zDj1b53ioH4MFqyHt1rN5XLao_Wb81BuDdAcDQjluNljv5S4PSFqXnyuj_XvH2QYUwCJ2WovmGO3R_f8Md45Sv9qO1nyxglKUZy5OficrK9g</recordid><startdate>20130301</startdate><enddate>20130301</enddate><creator>De la Torre Hernandez, Jose M., MD, PhD</creator><creator>Alfonso, Fernando, MD, PhD</creator><creator>Sanchez Recalde, Angel, MD</creator><creator>Jimenez Navarro, Manuel F., MD, PhD</creator><creator>Perez de Prado, Armando, MD</creator><creator>Hernandez, Felipe, MD</creator><creator>Abdul-Jawad Altisent, Omar, MD</creator><creator>Roura, Gerard, MD</creator><creator>Garcia Camarero, Tamara, MD</creator><creator>Elizaga, Jaime, MD, PhD</creator><creator>Rivero, Fernando, MD</creator><creator>Gimeno, Federico, MD, PhD</creator><creator>Calviño, Ramon, MD</creator><creator>Moreu, Jose, MD</creator><creator>Bosa, Francisco, MD, PhD</creator><creator>Rumoroso, Jose R., MD, PhD</creator><creator>Bullones, Juan A., MD</creator><creator>Gallardo, Arsenio, MD</creator><creator>Fernandez Diaz, Jose A., MD</creator><creator>Ruiz Arroyo, Jose R., MD</creator><creator>Aragon, Victor, MD</creator><creator>Masotti, Monica, MD</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7Z</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20130301</creationdate><title>Comparison of Paclitaxel -Eluting Stents (Taxus) and Everolimus -Eluting Stents (Xience) in Left Main Coronary Artery Disease With 3 Years Follow-Up (from the ESTROFA-LM Registry)</title><author>De la Torre Hernandez, Jose M., MD, PhD ; Alfonso, Fernando, MD, PhD ; Sanchez Recalde, Angel, MD ; Jimenez Navarro, Manuel F., MD, PhD ; Perez de Prado, Armando, MD ; Hernandez, Felipe, MD ; Abdul-Jawad Altisent, Omar, MD ; Roura, Gerard, MD ; Garcia Camarero, Tamara, MD ; Elizaga, Jaime, MD, PhD ; Rivero, Fernando, MD ; Gimeno, Federico, MD, PhD ; Calviño, Ramon, MD ; Moreu, Jose, MD ; Bosa, Francisco, MD, PhD ; Rumoroso, Jose R., MD, PhD ; Bullones, Juan A., MD ; Gallardo, Arsenio, MD ; Fernandez Diaz, Jose A., MD ; Ruiz Arroyo, Jose R., MD ; Aragon, Victor, MD ; Masotti, Monica, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-aeafddcbb2bd16eb6e4db5fcb8d09511f0082ace355409eb71c4158d2ac5aa9e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>Antineoplastic Agents, Phytogenic - pharmacokinetics</topic><topic>Cardiology</topic><topic>Cardiovascular</topic><topic>Cardiovascular disease</topic><topic>Coronary Angiography</topic><topic>Coronary Artery Disease - diagnostic imaging</topic><topic>Coronary Artery Disease - surgery</topic><topic>Coronary Restenosis - diagnostic imaging</topic><topic>Coronary Restenosis - epidemiology</topic><topic>Coronary Restenosis - prevention & control</topic><topic>Coronary vessels</topic><topic>Drug-Eluting Stents</topic><topic>Everolimus</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Heart attacks</topic><topic>Humans</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Incidence</topic><topic>Male</topic><topic>Paclitaxel - pharmacology</topic><topic>Registries</topic><topic>Retrospective Studies</topic><topic>Sirolimus - analogs & derivatives</topic><topic>Sirolimus - pharmacology</topic><topic>Spain - epidemiology</topic><topic>Stents</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>De la Torre Hernandez, Jose M., MD, PhD</creatorcontrib><creatorcontrib>Alfonso, Fernando, MD, PhD</creatorcontrib><creatorcontrib>Sanchez Recalde, Angel, MD</creatorcontrib><creatorcontrib>Jimenez Navarro, Manuel F., MD, PhD</creatorcontrib><creatorcontrib>Perez de Prado, Armando, MD</creatorcontrib><creatorcontrib>Hernandez, Felipe, MD</creatorcontrib><creatorcontrib>Abdul-Jawad Altisent, Omar, MD</creatorcontrib><creatorcontrib>Roura, Gerard, MD</creatorcontrib><creatorcontrib>Garcia Camarero, Tamara, MD</creatorcontrib><creatorcontrib>Elizaga, Jaime, MD, PhD</creatorcontrib><creatorcontrib>Rivero, Fernando, MD</creatorcontrib><creatorcontrib>Gimeno, Federico, MD, PhD</creatorcontrib><creatorcontrib>Calviño, Ramon, MD</creatorcontrib><creatorcontrib>Moreu, Jose, MD</creatorcontrib><creatorcontrib>Bosa, Francisco, MD, PhD</creatorcontrib><creatorcontrib>Rumoroso, Jose R., MD, PhD</creatorcontrib><creatorcontrib>Bullones, Juan A., MD</creatorcontrib><creatorcontrib>Gallardo, Arsenio, MD</creatorcontrib><creatorcontrib>Fernandez Diaz, Jose A., MD</creatorcontrib><creatorcontrib>Ruiz Arroyo, Jose R., MD</creatorcontrib><creatorcontrib>Aragon, Victor, MD</creatorcontrib><creatorcontrib>Masotti, Monica, MD</creatorcontrib><creatorcontrib>ESTROFA-LM Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Physical Education Index</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest_Research Library</collection><collection>Biochemistry Abstracts 1</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>De la Torre Hernandez, Jose M., MD, PhD</au><au>Alfonso, Fernando, MD, PhD</au><au>Sanchez Recalde, Angel, MD</au><au>Jimenez Navarro, Manuel F., MD, PhD</au><au>Perez de Prado, Armando, MD</au><au>Hernandez, Felipe, MD</au><au>Abdul-Jawad Altisent, Omar, MD</au><au>Roura, Gerard, MD</au><au>Garcia Camarero, Tamara, MD</au><au>Elizaga, Jaime, MD, PhD</au><au>Rivero, Fernando, MD</au><au>Gimeno, Federico, MD, PhD</au><au>Calviño, Ramon, MD</au><au>Moreu, Jose, MD</au><au>Bosa, Francisco, MD, PhD</au><au>Rumoroso, Jose R., MD, PhD</au><au>Bullones, Juan A., MD</au><au>Gallardo, Arsenio, MD</au><au>Fernandez Diaz, Jose A., MD</au><au>Ruiz Arroyo, Jose R., MD</au><au>Aragon, Victor, MD</au><au>Masotti, Monica, MD</au><aucorp>ESTROFA-LM Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of Paclitaxel -Eluting Stents (Taxus) and Everolimus -Eluting Stents (Xience) in Left Main Coronary Artery Disease With 3 Years Follow-Up (from the ESTROFA-LM Registry)</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>2013-03-01</date><risdate>2013</risdate><volume>111</volume><issue>5</issue><spage>676</spage><epage>683</epage><pages>676-683</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><coden>AJCDAG</coden><abstract>Evidence regarding therapy with drug-eluting stents in the left main coronary artery (LM) is based mostly on trials performed with first-generation drug-eluting stents. The aim of this study was to evaluate long-term clinical outcomes after treatment for unprotected LM disease with paclitaxel-eluting stents (PES) and everolimus-eluting stents (EES). The ESTROFA-LM is a multicenter retrospective registry including consecutive patients with unprotected LM disease treated with PES or EES. A total of 770 patients have been included at 21 centers, 415 with treated PES and 355 with EES. Treatment with 2 stents was more frequent with PES (17% vs 10.4%, p = 0.007), whereas intravascular ultrasound was more frequently used with EES (35.2% vs 26%, p = 0.006). The 3-year death and infarction survival rates were 86.1% for PES and 87.3% for EES (p = 0.50) and for death, infarction, and target lesion revascularization were 83.6% versus 82% (p = 0.60), respectively. Definite or probable thrombosis was 1.6% for PES and 1.4% for EES (p = 0.80). The use of 2 stents, age, diabetes, and acute coronary syndromes were independent predictors of mortality. In the subgroup of distal lesions, the use of intravascular ultrasound was an independent predictor of better outcome. Comparison of propensity score–matched groups did not yield differences between the 2 stents. In conclusion, the results of this multicenter registry show comparable safety and efficacy at 3 years for PES and EES in the treatment of LM disease. The use of bifurcation stenting techniques in distal lesions was a relevant independent predictor for events. The use of intravascular ultrasound appears to have a positive impact on patients treated for LM distal disease.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23273715</pmid><doi>10.1016/j.amjcard.2012.11.019</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9149 |
| ispartof | The American journal of cardiology, 2013-03, Vol.111 (5), p.676-683 |
| issn | 0002-9149 1879-1913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1288994706 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Aged Antineoplastic Agents, Phytogenic - pharmacokinetics Cardiology Cardiovascular Cardiovascular disease Coronary Angiography Coronary Artery Disease - diagnostic imaging Coronary Artery Disease - surgery Coronary Restenosis - diagnostic imaging Coronary Restenosis - epidemiology Coronary Restenosis - prevention & control Coronary vessels Drug-Eluting Stents Everolimus Female Follow-Up Studies Heart attacks Humans Immunosuppressive Agents - pharmacology Incidence Male Paclitaxel - pharmacology Registries Retrospective Studies Sirolimus - analogs & derivatives Sirolimus - pharmacology Spain - epidemiology Stents Time Factors Treatment Outcome |
| title | Comparison of Paclitaxel -Eluting Stents (Taxus) and Everolimus -Eluting Stents (Xience) in Left Main Coronary Artery Disease With 3 Years Follow-Up (from the ESTROFA-LM Registry) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T05%3A53%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20Paclitaxel%20-Eluting%20Stents%20(Taxus)%20and%20Everolimus%20-Eluting%20Stents%20(Xience)%20in%20Left%20Main%20Coronary%20Artery%20Disease%20With%203%20Years%20Follow-Up%20(from%20the%20ESTROFA-LM%20Registry)&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=De%20la%20Torre%20Hernandez,%20Jose%20M.,%20MD,%20PhD&rft.aucorp=ESTROFA-LM%20Study%20Group&rft.date=2013-03-01&rft.volume=111&rft.issue=5&rft.spage=676&rft.epage=683&rft.pages=676-683&rft.issn=0002-9149&rft.eissn=1879-1913&rft.coden=AJCDAG&rft_id=info:doi/10.1016/j.amjcard.2012.11.019&rft_dat=%3Cproquest_cross%3E1288994706%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1400213309&rft_id=info:pmid/23273715&rft_els_id=1_s2_0_S0002914912024526&rfr_iscdi=true |